Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan

NCT01514240 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01514240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01514240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2012
Completion date
September 30, 2014
Enrollment
123 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease